Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1158/2159-8290.CD-16-0716 http://scihub22266oqcxt.onion/10.1158/2159-8290.CD-16-0716 C5293166!5293166 !27655435     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27655435 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Cancer+Discov 2016 ; 6 (10 ): 1090-1105 Nephropedia Template TP {{tp|p=27655435 |t=2016. Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy |pdf=|usr=}}{{27655435 }} gab.com Text Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy JO: Cancer Discov http://www.kidney.de/pget.php?&tw=1&pmid=27655435 #FOAvip The PI3K pathway is hyperactivated in most cancers, yet the capacity of PI3K inhibitors to induce tumor cell death is limited. The efficacy of PI3K inhibition can also derive from interference with the cancer cells' ability to respond to stromal signals, as illustrated by the approved PI3K? inhibitor idelalisib in B-cell malignancies. Inhibition of the leukocyte-enriched PI3K? or PI3K? may unleash antitumor T-cell responses by inhibiting regulatory T cells and immune-suppressive myeloid cells. Moreover, tumor angiogenesis may be targeted by PI3K inhibitors to enhance cancer therapy. Future work should therefore also explore the effects of PI3K inhibitors on the tumor stroma, in addition to their cancer cell-intrinsic impact. SIGNIFICANCE: The PI3K pathway extends beyond the direct regulation of cancer cell proliferation and survival. In B-cell malignancies, targeting PI3K purges the tumor cells from their protective microenvironment. Moreover, we propose that PI3K isoform-selective inhibitors may be exploited in the context of cancer immunotherapy and by targeting angiogenesis to improve drug and immune cell delivery. Cancer Discov; 6(10); 1090-105. ©2016 AACR. Twit Text FOAVip Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy ????Cancer Discov http://www.kidney.de/pget.php?&tw=1&pmid=27655435 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27655435 #FOAvip English Wikipedia <ref>{{Cite pmid|27655435 }}</ref> Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy #MMPMID27655435 Okkenhaug K ; Graupera M ; Vanhaesebroeck B Cancer Discov 2016[Oct]; 6 (10 ): 1090-1105 PMID27655435 show ga The PI3K pathway is hyperactivated in most cancers, yet the capacity of PI3K inhibitors to induce tumor cell death is limited. The efficacy of PI3K inhibition can also derive from interference with the cancer cells' ability to respond to stromal signals, as illustrated by the approved PI3K? inhibitor idelalisib in B-cell malignancies. Inhibition of the leukocyte-enriched PI3K? or PI3K? may unleash antitumor T-cell responses by inhibiting regulatory T cells and immune-suppressive myeloid cells. Moreover, tumor angiogenesis may be targeted by PI3K inhibitors to enhance cancer therapy. Future work should therefore also explore the effects of PI3K inhibitors on the tumor stroma, in addition to their cancer cell-intrinsic impact. SIGNIFICANCE: The PI3K pathway extends beyond the direct regulation of cancer cell proliferation and survival. In B-cell malignancies, targeting PI3K purges the tumor cells from their protective microenvironment. Moreover, we propose that PI3K isoform-selective inhibitors may be exploited in the context of cancer immunotherapy and by targeting angiogenesis to improve drug and immune cell delivery. Cancer Discov; 6(10); 1090-105. ©2016 AACR. |Angiogenesis Inhibitors/*pharmacology/therapeutic use [MESH] |Cell Proliferation/drug effects [MESH] |Cell Survival/drug effects [MESH] |Combined Modality Therapy [MESH] |Humans [MESH] |Immunotherapy [MESH] |Molecular Targeted Therapy/methods [MESH] |Neoplasms/*drug therapy/enzymology [MESH] |Phosphoinositide-3 Kinase Inhibitors [MESH] |Protein Kinase Inhibitors/*pharmacology/therapeutic use [MESH] |Purines/*pharmacology/therapeutic use [MESH] |Quinazolinones/*pharmacology/therapeutic use [MESH] |Signal Transduction [MESH]Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stro(epmc).pdf DeepDyve Pubget Overpricing